OFI Invest Asset Management cut its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 96.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,092 shares of the healthcare product maker’s stock after selling 210,140 shares during the quarter. OFI Invest Asset Management’s holdings in Abbott Laboratories were worth $688,000 as of its most recent SEC filing.
A number of other institutional investors also recently bought and sold shares of ABT. Signature Resources Capital Management LLC purchased a new stake in Abbott Laboratories in the fourth quarter worth $29,000. Transcendent Capital Group LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at $29,000. Richardson Financial Services Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at $29,000. Redmont Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories during the first quarter valued at $30,000. Finally, True Wealth Design LLC increased its stake in shares of Abbott Laboratories by 1,677.8% during the fourth quarter. True Wealth Design LLC now owns 320 shares of the healthcare product maker’s stock valued at $35,000 after buying an additional 302 shares during the period. 75.18% of the stock is currently owned by institutional investors.
Abbott Laboratories Stock Performance
NYSE ABT traded up $0.06 during trading hours on Friday, reaching $111.00. The stock had a trading volume of 4,643,293 shares, compared to its average volume of 6,033,353. The stock has a fifty day moving average of $105.47 and a 200 day moving average of $108.76. The stock has a market cap of $193.10 billion, a P/E ratio of 34.58, a price-to-earnings-growth ratio of 2.74 and a beta of 0.72. Abbott Laboratories has a 52-week low of $89.67 and a 52-week high of $121.64. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.11 and a current ratio of 1.68.
Abbott Laboratories Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Thursday, August 15th. Stockholders of record on Monday, July 15th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 1.98%. The ex-dividend date was Monday, July 15th. Abbott Laboratories’s payout ratio is 68.54%.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on ABT. Royal Bank of Canada restated an “outperform” rating and set a $125.00 price target on shares of Abbott Laboratories in a research note on Tuesday, June 4th. Edward Jones downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, July 30th. Citigroup reduced their target price on shares of Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating for the company in a report on Wednesday, May 22nd. Evercore ISI reduced their target price on shares of Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Finally, The Goldman Sachs Group started coverage on Abbott Laboratories in a research note on Thursday, May 30th. They set a “buy” rating and a $121.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $121.00.
View Our Latest Analysis on Abbott Laboratories
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- The How and Why of Investing in Gold Stocks
- This Small Cap Wealth Management Stock Could Provide Big Returns
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.